Zydus Cadila secures DCGI approval for launch of NCE for diabetes

The Company has secured the approval for its new chemical entity, Lipaglyn.


New Delhi, June 5, 2013: Cadila Healthcare recently said that the Indian drug regulator has approved the new chemical identity of the company, Lipaglyn, to be used for treating a type of diabetes for launch in the country.


The company said in a filing to BSE that the Drug Controller of India (DCGI) has approved Lipaglyn to be used for treating 'diabetic dyslipidemeia' for launch.


It may be noted here that diabetic dyslipidemeia is a condition where a person is diabetic and has elevated levels of total cholesterol.


The company is of a view that Lipaglyn provides patients suffering from diabetic dyslipidemia the option for once-daily oral therapy that has a beneficial effect on both lipid parameters as well as glycemic control.


* Indicates mandatory field.
Please wait while comments are being sent...